EZR and cervical carcinoma: Interestingly, the perinuclear localization of ezrin was observed in 51.4% of ezrin-positive cervical cancer cases, and the positive rate of perinuclear localization was higher in well (75.3%) and moderately (44.2%) differentiated cervical cancers than in poorly differentiated cases (21.2%) (P<0.05).